Empagliflozin for treating chronic kidney disease

  • Technology appraisal guidance
  • TA942
  • Published: 
Download guidance (PDF)

2 Information about empagliflozin

Marketing authorisation indication

2.1

Empagliflozin (Jardiance, Boehringer Ingelheim) is indicated for the treatment of 'chronic kidney disease (CKD) in adults'.

Dosage in the marketing authorisation

Price

2.3

The list price for empagliflozin is £36.59 for 28 tablets (10 mg and 25 mg) (excluding VAT; BNF online, accessed October 2023).

2.4

Costs may vary in different settings because of negotiated procurement discounts.